7,575.62

+198.76

+2.69%

52,510.71

+1,224.98

+2.39%

25,343.18

+763.76

+3.11%

2,850.09

+95.99

+3.49%

4.8640

+0.0050

+0.10%

19.75

-5.89

-22.96%

4,154.90

+80.00

+1.96%

74,736.99

-906.59

-1.20%

Crude Oil Dec 26

86.10

-4.73

-5.21%

US Private Equity

10,772.76

+11.86

+0.11%

NasdaqCM - Delayed Quote USD

Tvardi Therapeutics, Inc. (TVRD)

1.3500 +0.3980 (+41.81%)

As of 3:27:19 PM EST. Market Open.

Loading Chart for TVRD

Chart Range Bar

Interval:

In partnership with ChartIQ

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Tvardi: Q3 Earnings Snapshot

Tvardi: Q3 Earnings Snapshot

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics to Participate in Upcoming Investor Events

Mobilize your Website

View Site in Mobile | Classic

Share by: